Trials / Active Not Recruiting
Active Not RecruitingNCT04002180
Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]
Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Crohn's Disease]
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 335 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.
Detailed description
The drug being tested in this survey is called vedolizumab for IV infusion 300 mg. This drug is being tested to treat patients who have CD. This survey is an observational (non-interventional) study and will look at the long-term safety and effectiveness of vedolizumab for IV infusion 300 mg in the routine clinical setting. The planned number of observed patients will be approximately 300. This multi-center observational trial will be conducted in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vedolizumab (Genetical Recombination) | Vedolizumab IV infusion |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2019-06-28
- Last updated
- 2026-01-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04002180. Inclusion in this directory is not an endorsement.